COVID-19 and Vitamin D (Co-VIVID Study): a systematic review and meta-analysis of randomized controlled trials
Varikasuvu et al.,
COVID-19 and Vitamin D (Co-VIVID Study): a systematic review and meta-analysis of randomized controlled trials,
Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2022.2035217 (meta analysis)
Meta analysis of 6 vitamin D treatment RCTs, showing statistically significant improvements for pooled outcomes and PCR positivity, and positive but not statistically significant improvements for mortality, mechanical ventilation, ICU admission, and severity.
Currently there are
104 vitamin D studies and meta analysis shows:
Varikasuvu et al., 25 Aug 2021, peer-reviewed, 7 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.08.22.21262216; this version posted August 25, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
COVID-19 and Vitamin D (Co-VIVID Study): a systematic review and meta-analysis of
randomized controlled trials
Running title: COVID-19 and Vitamin D (Co-VIVID Study)
Seshadri Reddy Varikasuvu a*, Balachandar Thangappazham b, Hemanth Raj c
a
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Deoghar,
Jharkhand, India
b
StepOne NGO, Pegasus Block, Malleswaram West, Bengaluru, Karnataka, India
c
Department of Medicine, Mount Medical Centre, Tamil Nadu, India
*Corresponding author:
Dr. Seshadri Reddy Varikasuvu
Assistant Professor, Department of Biochemistry
All India Institute of Medical Sciences
AIIMS, Deoghar, Jharkhand-814142, India
Phone: +91 81 0 61 45 001
E-mail: lifeschemistry@live.com
https://orcid.org/0000-0002-2230-4676
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.08.22.21262216; this version posted August 25, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Abstract
Background: Vitamin D levels have been reported to be associated with COVID-19
susceptibility, severity and mortality events.. We performed a meta-analysis of randomized
controlled trials (RCTs) to evaluate the use of vitamin D intervention on COVID-19 outcomes.
Methods: Literature search was conducted using PubMed, Cochrane library, and
ClinicalTrials.gov databases (latest search on August 5, 2021). We included RCTs reporting the
use of vitamin D intervention to control/placebo group in COVID-19. Two independent
researchers did literature search, abstracted data, and the risk of bias assessment. Results: A total
of 6 RCTs with 551 COVID-19 patients were included. The overall collective evidence pooling
all the outcomes across all RCTs indicated the beneficial use of vitamin D intervention in
COVID-19 (relative risk, RR = 0.60, 95% CI 0.40 to 0.92, Z=2.33, p=0.02, I2 = 48%). However,
no statistical significance was observed for individual outcomes of ICU care (RR = 0.11, 95% CI
0.15 to 1.30, Z=1.48, p=0.14, I2 = 66%) and mortality (RR = 0.78, 95% CI 0.25 to 2.40, Z=0.66,
p=0.02, I2 = 33%), though decreased rates were noted. The rates of RT-CR positivity was
significantly decreased in the intervention group as compared to the non-vitamin D groups (RR =
0.46, 95% CI 0.24 to 0.89, Z=2.31, p=0.02, I2 = 0%). Conclusion: COVID-19 patients
supplemented with vitamin D are more likely to demonstrate fewer rates of ICU admission,
mortality events and RT-PCR positivity. However, no statistical significance has been achieved
for individual outcomes of ICU and deaths. More RCTs and completion of ongoing trials largely
needed to precisely establish the association between vitamin D use and COVID-19.
Keywords: Cholecalciferol; COVID-19; Randomized controlled trial; SARS-Cov-2; Vitamin D
2
medRxiv preprint doi: https://doi.org/10.1101/2021.08.22.21262216; this version posted August 25,..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit